{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:43:56Z","timestamp":1794667436225,"version":"4.9.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1053\/j.semnuclmed.2025.03.004","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T11:10:58Z","timestamp":1744456258000},"page":"538-547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Global experience in brain amyloid imaging"],"prefix":"10.1053","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4423-5496","authenticated-orcid":false,"given":"Luca","family":"Filippi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6176-2805","authenticated-orcid":false,"given":"Orazio","family":"Schillaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.medengphy.2024.104269","article-title":"Advances and future trends in the detection of beta-amyloid: A comprehensive review","volume":"135","author":"Ganguly","year":"2025","journal-title":"Med Eng Phys"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0002","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2217\/nmt-2022-0013","article-title":"The AT(N) system for describing biological changes in Alzheimer's disease: A plain language summary","volume":"12","author":"Hampel","year":"2022","journal-title":"Neurodegener Dis Manag"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0003","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1097\/RLU.0b013e31829b9e5f","article-title":"Amyloid PET\/MRI in the differential diagnosis of dementia","volume":"39","author":"Vercher-Conejero","year":"2014","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0004","doi-asserted-by":"crossref","first-page":"S603","DOI":"10.3233\/JAD-240349","article-title":"Positron emission tomography\/computed tomography imaging in therapeutic clinical trials in Alzheimer's Disease: An overview of the current State of the art of research","volume":"101","author":"Triumbari","year":"2024","journal-title":"J Alzheimers Dis"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0005","first-page":"268","article-title":"18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease","volume":"8","author":"Filippi","year":"2018","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0006","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MNM.0000000000001688","article-title":"New impetus for amyloid-PET imaging following the Food and Drug Administration approval of a new Alzheimer's disease treatment","volume":"44","author":"Balaji","year":"2023","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0007","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3390\/diagnostics13101682","article-title":"Imaging of tauopathies with PET ligands: State of the art and future outlook","volume":"13","author":"Conte","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0008","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/cells14030168","article-title":"Modulating neuroinflammation as a prospective therapeutic target in Alzheimer's disease","volume":"14","author":"Lee","year":"2025","journal-title":"Cells"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0009","article-title":"Clinical diagnoses and characterization of patients with amyloid-negative amyloid-beta, p-tau, and neurofilament light chain (ATN) profiles","volume":"16","author":"Barnett","year":"2024","journal-title":"Cureus"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0010","doi-asserted-by":"crossref","first-page":"7481","DOI":"10.3390\/ijms21207481","article-title":"Positron emission tomography (PET) and neuroimaging in the personalized approach to neurodegenerative causes of dementia","volume":"21","author":"Ricci","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0011","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/brain\/awad005","article-title":"Anti-amyloid antibody therapies in Alzheimer's disease","volume":"146","author":"Perneczky","year":"2023","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0012","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: The amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0013","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/JAD-2006-9S317","article-title":"Alzheimer's disease: The amyloid cascade hypothesis: An update and reappraisal","volume":"9","author":"Hardy","year":"2006","journal-title":"J Alzheimers Dis"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0014","article-title":"(11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)","volume":"2014","author":"Zhang","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0015","first-page":"890","article-title":"Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease","volume":"13","author":"Okamura","year":"2010","journal-title":"IDrugs"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0016","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3233\/JAD-170762","article-title":"Antemortem-postmortem correlation of florbetapir (18F) PET amyloid imaging with quantitative biochemical measures of A\u03b242 but not A\u03b240","volume":"61","author":"Beach","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0017","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","article-title":"Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density","volume":"72","author":"Curtis","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0018","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","article-title":"Beta-amyloid imaging with florbetaben","volume":"3","author":"Sabri","year":"2015","journal-title":"Clin Transl Imaging"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0019","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00259-012-2088-x","article-title":"Comparison of 11C-PiB and 18F-florbetaben for a\u03b2 imaging in ageing and Alzheimer's disease","volume":"39","author":"Villemagne","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0020","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/jon.12601","article-title":"18F-Florbetaben PET\/CT to assess Alzheimer's Disease: A new analysis method for regional amyloid quantification","volume":"29","author":"Alongi","year":"2019","journal-title":"J Neuroimaging"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0021","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3233\/JAD-190533","article-title":"Ultrasensitive detection of plasma amyloid-\u03b2 as a biomarker for cognitively normal elderly individuals at risk of Alzheimer's disease","volume":"71","author":"Chatterjee","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0022","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/wjnm.WJNM_5_17","article-title":"Comparison of standardized uptake value ratio calculations in amyloid positron emission tomography brain imaging","volume":"17","author":"Kne\u0161aurek","year":"2018","journal-title":"World J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0023","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fnagi.2019.00251","article-title":"Longitudinal assessment of amyloid-\u03b2 deposition by [18F]-flutemetamol PET imaging compared with [11C]-PIB across the spectrum of Alzheimer's disease","volume":"11","author":"Hatashita","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0024","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","article-title":"Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline","volume":"28","author":"Ossenkoppele","year":"2022","journal-title":"Nat Med"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0025","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13195-017-0283-5","article-title":"On the path to 2025: Understanding the Alzheimer's disease continuum","volume":"9","author":"Aisen","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0026","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00259-023-06177-5","article-title":"FDA approval of lecanemab: The real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective","volume":"50","author":"Verger","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0027","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1002\/alz.13158","article-title":"Longitudinal amyloid and tau PET imaging in Alzheimer's disease: A systematic review of methodologies and factors affecting quantification","volume":"19","author":"Bollack","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0028","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14338","article-title":"Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup","volume":"21","author":"Rabinovici","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0029","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1212\/WNL.0000000000201389","article-title":"Impact of amyloid and tau PET on changes in diagnosis and patient management","volume":"100","author":"Shimohama","year":"2023","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0030","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/joim.12167","article-title":"Health economic evaluation of treatments for Alzheimer's disease: Impact of new diagnostic criteria","volume":"275","author":"Wimo","year":"2014","journal-title":"J Intern Med"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0031","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.2967\/jnumed.116.174615","article-title":"SNMMI procedure Standard\/EANM practice guideline for Amyloid PET imaging of the brain 1.0","volume":"57","author":"Minoshima","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2019.101846","article-title":"Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC)","volume":"23","author":"Chincarini","year":"2019","journal-title":"Neuroimage Clin"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0033","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3233\/JAD-160232","article-title":"Standardized uptake value ratio-independent evaluation of brain amyloidosis","volume":"54","author":"Chincarini","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0034","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","article-title":"Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers","volume":"16","author":"Frisoni","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0035","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","article-title":"Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization","volume":"74","author":"Petersen","year":"2010","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0036","article-title":"The worldwide Alzheimer's disease neuroimaging initiative: ADNI-3 updates and global perspectives","volume":"7","author":"Weber","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0037","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14321","article-title":"Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials","volume":"21","author":"Weiner","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0038","doi-asserted-by":"crossref","first-page":"228fs13","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 study: Stopping AD before symptoms begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0039","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/alz.12748","article-title":"The AHEAD 3-45 study: Design of a prevention trial for Alzheimer's disease","volume":"19","author":"Rafii","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0040","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1002\/alz.14242","article-title":"The Alzheimer's Disease Neuroimaging Initiative-4 (ADNI-4) Engagement Core: A culturally informed, community-engaged research (CI-CER) model to advance brain health equity","volume":"20","author":"Rivera Mindt","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0041","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40120-022-00416-x","article-title":"Non-drug therapies for Alzheimer's disease: A review","volume":"12","author":"Li","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0042","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/jamaneurol.2022.3157","article-title":"Racial and ethnic differences in amyloid PET positivity in individuals with mild cognitive impairment or dementia: A secondary analysis of the imaging dementia-evidence for amyloid scanning (IDEAS) cohort study","volume":"79","author":"Wilkins","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0043","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1007\/s00259-016-3393-6","article-title":"Dual-phase amyloid PET: Hitting two birds with one stone","volume":"43","author":"Valentina","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0044","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00259-011-2051-2","article-title":"Correlation of early-phase 18F-florbetapir (AV-45\/Amyvid) PET images to FDG images: Preliminary studies","volume":"39","author":"Hsiao","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0045","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.neurobiolaging.2014.12.036","article-title":"Regional cerebral blood flow estimated by early PiB uptake is reduced in mild cognitive impairment and associated with age in an amyloid-dependent manner","volume":"36","author":"Gietl","year":"2015","journal-title":"Neurobiol Aging"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0046","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139926","article-title":"Early-phase 11C-PiB PET in amyloid angiopathy-related symptomatic cerebral hemorrhage: Potential diagnostic value?","volume":"10","author":"Farid","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0047","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","article-title":"Quantification of amyloid PET for future clinical use: A state-of-the-art review","volume":"49","author":"Pemberton","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.629442","article-title":"Brain SPECT as a biomarker of neurodegeneration in dementia in the era of molecular imaging: Still a valid option?","volume":"12","author":"Ferrando","year":"2021","journal-title":"Front Neurol"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0049","doi-asserted-by":"crossref","first-page":"8206","DOI":"10.1002\/alz.14289","article-title":"Need to adapt Alzheimer's disease criteria in Latin America","volume":"20","author":"Custodio","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/cbr.2006.21.41","article-title":"Usefulness of SPECT\/CT with a hybrid camera for the functional anatomical mapping of primary brain tumors by [Tc99m] tetrofosmin","volume":"21","author":"Filippi","year":"2006","journal-title":"Cancer Biother Radiopharmaceutic"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0051","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: Images are more than pictures, they are data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0052","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3390\/diagnostics12040929","article-title":"The role and potential of 18F-FDG PET\/CT in malignant melanoma: Prognostication, monitoring response to targeted and immunotherapy, and radiomics","volume":"12","author":"Filippi","year":"2022","journal-title":"Diagnostics"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0053","first-page":"2024","article-title":"Use of artificial intelligence in imaging dementia","volume":"13","author":"Aljuhani","year":"1965","journal-title":"Cells"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2024.108098","article-title":"Alzheimer's disease Neuroimaging initiative: Predicting amyloid positivity from FDG-PET images using radiomics: A parsimonious model","volume":"247","author":"Rasi","year":"2024","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0055","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2967\/jnumed.124.267767","article-title":"Performance characteristics of the NeuroEXPLORER, a next-generation Human brain PET\/CT imager","volume":"65","author":"Li","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.03.004_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2024.120779","article-title":"Evaluation of a novel PET tracer [18F]-Florbetazine for Alzheimer's disease diagnosis and \u03b2-amyloid deposition quantification","volume":"298","author":"Wu","year":"2024","journal-title":"Neuroimage"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T17:07:14Z","timestamp":1751476034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825000303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0001299825000303"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.03.004","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global experience in brain amyloid imaging","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}